1.

Table e-3: Genetic data of A-T patients with mild phenotypes from the Dutch cohort and literature.

1.

Table e-1: Clinical and laboratory data of 105 A-T patients with mild phenotypes from the Dutch cohort and literature.

1.

Table e-1: Clinical and laboratory data of 105 A-T patients with mild phenotypes from the Dutch cohort and literature. ...

1.

Table e-3: Genetic data of A-T patients with mild phenotypes from the Dutch cohort and literature. ...

1.

The assessment of the April 2020 chernobyl wildfires and their impact on Cs-137 levels in Belgium and The Netherlands

2.

The assessment of the April 2020 chernobyl wildfires and their impact on Cs-137 levels in Belgium and The Netherlands

3.

The assessment of the April 2020 chernobyl wildfires and their impact on Cs-137 levels in Belgium and The Netherlands

1.

Efficacy of olaparib in advanced cancers with germline or somatic mutations in BRCA1, BRCA2, CHEK2 and ATM, a Belgian Precision tumor-agnostic phase II study.

2.

Efficacy of olaparib in advanced cancers with germline or somatic mutations in BRCA1, BRCA2, CHEK2 and ATM, a Belgian Precision tumor-agnostic phase II study.

3.

Efficacy of olaparib in advanced cancers with germline or somatic mutations in BRCA1, BRCA2, CHEK2 and ATM, a Belgian Precision tumor-agnostic phase II study.

4.

Efficacy of olaparib in advanced cancers with germline or somatic mutations in BRCA1, BRCA2, CHEK2 and ATM, a Belgian Precision tumor-agnostic phase II study.

5.

Efficacy of olaparib in advanced cancers with germline or somatic mutations in BRCA1, BRCA2, CHEK2 and ATM, a Belgian Precision tumor-agnostic phase II study.

1.

Efficacy of olaparib in advanced cancers with germline or somatic mutations in BRCA1, BRCA2, CHEK2 and ATM, a Belgian Precision tumor-agnostic phase II study

2.

Efficacy of olaparib in advanced cancers with germline or somatic mutations in BRCA1, BRCA2, CHEK2 and ATM, a Belgian Precision tumor-agnostic phase II study

3.

Efficacy of olaparib in advanced cancers with germline or somatic mutations in BRCA1, BRCA2, CHEK2 and ATM, a Belgian Precision tumor-agnostic phase II study

1.

Discriminatory fees, coordination and investment in shared ATM networks

1.

Life cycle assessment of cash payments in the Netherlands

1.

Preventing Money Laundering and Terrorist Financing : A Practical Guide for Bank Supervisors ; Prevención del lavado de dinero y del financiamiento al terrorismo : una guía práctic...